ClinicalTrials.gg
RecruitingNCT07733024DSC-NECUpdated Sep 28, 2026

Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer

A Phase 2 interventional study of 68Ga-PFD3 in Neuroendocrine Tumors, sponsored by Tingting Yuan. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Tingting Yuan · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Neuroendocrine Tumors with a site in China — 23 open to participants now, 29 under way, 2 of them phase 3. Neuroendocrine Tumors · China.

Planned enrollment
10th of 48
200 · median 65
Started
2026
with 2 others
Phase 2
14 of 63
4 open now
Primary completion
2027-12
later than 24 of 28 live
Registered
62nd of 63
by date

Among the 63 studies in Neuroendocrine Tumors with a site in China, this one is the 10th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 24 of the 28 other live ones, and was the 62nd registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

23 of the 63 studies in Neuroendocrine Tumors with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Neuroendocrine Tumors with a site in China, or all of them as a file.
02

Study summary

This study is testing a new PET/CT scan that uses a special tracer called [⁶⁸Ga]Ga-DLL3 nanobody to see if it can better detect cancer spread (metastases) in people with neuroendocrine tumors than the standard scans currently used (FDG PET/CT or PSMA PET/CT). DLL3 is a protein found on the surface of many neuroendocrine tumor cells, and the new tracer is designed to stick to this protein, making tumors visible on the scan. The goal is to find out whether this new imaging method can give doctors more accurate information about where the cancer has spread and help them choose the most appropriate treatment for each patient.

The study is prospective, multi-center, and self-controlled, meaning each participant will receive both the new scan and the standard scan, allowing a direct side-by-side comparison in the same person. Depending on the type of neuroendocrine tumor, participants will be assigned to one of two groups: one group will be compared with FDG PET/CT and the other with PSMA PET/CT. The two scans will be performed within two weeks of each other, and all images will be read by independent experts who do not know the patient's clinical history, to ensure objective and unbiased results.

The investigators plan to enroll about 180-200 patients aged 18 or older who have confirmed neuroendocrine tumors with at least two metastatic sites. The total duration of participation is approximately 6 months, consisting of a screening period of up to 14 days, two imaging scans completed within 2 days, and a final follow-up visit at 6 months to evaluate participants' health and disease progression. Participation is entirely voluntary, and participants may withdraw at any time without affecting participants' standard medical care.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Neuroendocrine Tumors
  • [⁶⁸Ga]Ga-DLL3 Nanobody
  • DLL3 expression
  • Comparative Study
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and ≤ 80 years at the time of signing the form, male or female.
  • or cytologically confirmed neuroendocrine neoplasms (NENs), including but not limited to small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), gastroenteropancreatic neuroendocrine tumors (GEP-NENs), or other NEN subtypes.
  • Patients with strong clinical and radiological suspicion of NENs based on imaging (CT/MRI/conventional PET/CT) and clinical presentation.
  • At least 2 evaluable lesions (multiple metastases) confirmed by conventional imaging (CT/MRI/PET/CT).
  • (ECOG) performance status 0-2. > 3 months.
  • Voluntarily agrees to participate and provides written informed consent.
  • Females of and male participants agree to use reliable methods for 6 months after the last study drug administration.
  • Willing and able to comply with scheduled visits, diagnostic procedures, clinical laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Known severe immediate-type or anaphylactic reaction to DLL3-targeted tracers, nanobody proteins, chelators, buffer components, or .
  • Pregnant or breastfeeding women.
  • Estimated (eGFR) \< 30 mL/min/1.73m².
  • (ALT) or aspartate aminotransferase (AST) > 3 × (ULN).
  • Total > 1.5 × ULN.
  • Inability to tolerate or cooperate with PET/CT imaging procedures, including but not limited to: severe claustrophobia, inability to remain supine and still for at least 30 minutes, or inability to establish adequate intravenous access.
  • Received chemotherapy, biological therapy, endocrine therapy, molecular targeted therapy, or drug therapy within 4 weeks prior to enrollment.
  • Currently participating in another interventional clinical trial.
  • Prior exposure to any DLL3-targeted therapeutic agent (e.g., Tarlatamab, bispecific T-cell engagers, or DLL3-targeted radioimmunotherapy) or DLL3-targeted radiotracer.
  • Prior radionuclide therapy or diagnostic scan with an interval of less than 10 physical half-lives of the administered radionuclide prior to study tracer administration.
  • History of any other within 5 years prior to screening, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies with negligible risk of recurrence in the investigator's opinion.
  • abnormalities on physical examination, (ECG), or clinical laboratory tests during screening that, in the investigator's opinion, may compromise safety or study compliance.
  • Any other condition that, in the investigator's opinion, makes the patient unsuitable for study participation (e.g., severe psychiatric disorders, substance abuse, poor compliance).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    [⁶⁸Ga]Ga-DLL3 Nanobody PET/CT

    Participants receive a single intravenous injection of \[⁶⁸Ga\]Ga-DLL3 nanobody (a novel radiotracer targeting Delta-like ligand 3 \[DLL3\]), followed by whole-body PET/CT imaging at approximately 2 hours post-injection. DLL3 is a protein aberrantly expressed on the surface of neuroendocrine tumor cells. The nanobody is engineered for high-affinity and specificity binding to DLL3, enabling non-invasive visualization of DLL3-expressing tumor lesions. The total injected protein mass and molar activity are controlled according to the study protocol to ensure consistent imaging quality. PET/CT images are acquired from skull base to mid-thigh (extended to feet if clinically indicated) using a standardized acquisition protocol. Image reconstruction is performed with consistent algorithms across all participants. Each subject serves as their own control, with the DLL3 PET/CT results compared to their conventional imaging (FDG PET/CT or PSMA PET/CT) performed within 2 weeks. The scan is performed

    Drug: 68Ga-PFD3

Interventions

  • Drug68Ga-PFD3

    \[⁶⁸Ga\]Ga-PFD3 is a novel PET tracer constructed by conjugating a DLL3-specific nanobody (single-domain antibody, \~15 kDa) with a chelator for ⁶⁸Ga radiolabeling. DLL3 (Delta-like ligand 3) is a cell-surface protein that is rarely expressed in healthy adult tissues but is overexpressed in over 80% of small cell lung cancer and in other high-grade neuroendocrine tumors, making it an attractive target for molecular imaging. The nanobody platform offers advantages over conventional monoclonal antibody-based tracers (e.g., \[⁸⁹Zr\]Zr-DFO-SC16.56): smaller size (\~15 kDa vs. \~150 kDa) enables superior tissue penetration, rapid blood clearance, and shorter in vivo residence time, allowing same-day PET/CT imaging within hours post-injection. Participants receive a single intravenous injection of \[⁶⁸Ga\]Ga-PFD3 (activity: 111-185 MBq; protein mass and molar activity controlled per protocol), followed by whole-body PET/CT acquisition at approximately 2 hours post-injection. Images are acquired from

    Also known as: 68Ga-DLL3

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy of [⁶⁸Ga]Ga-DLL3 Nanobody PET/CT in Detecting Metastatic Lesions

    Sensitivity and specificity of \[⁶⁸Ga\]Ga-DLL3 nanobody PET/CT for detecting metastatic lesions in patients with neuroendocrine neoplasms, using a composite reference standard (incorporating histopathology, conventional imaging \[FDG/PSMA PET/CT, diagnostic CT/MRI\], and 6-month clinical/imaging follow-up) as the truth standard.

    Time frame: Baseline (within 14 days of enrollment) and Month 6

Secondary outcomes

  1. Lesion Detection Rate

    Per-lesion detection rate of \[⁶⁸Ga\]Ga-DLL3 PET/CT compared to FDG or PSMA PET/CT, stratified by anatomical location (e.g., liver, bone, lung, brain, lymph nodes).

    Time frame: Baseline (within 14 days of enrollment)

  2. Clinical Management Change Rate

    Proportion of patients whose clinical management (e.g., staging, treatment selection, or biopsy site decision) is altered based on \[⁶⁸Ga\]Ga-DLL3 PET/CT results compared to conventional imaging.

    Time frame: Baseline (at time of image interpretation, within 14 days of enrollment)

  3. Safety and Tolerability

    Incidence, severity, and causality of adverse events (graded per CTCAE v5.0) following single intravenous injection of \[⁶⁸Ga\]Ga-DLL3 nanobody, including injection site reactions, allergic reactions, and any serious adverse events.

    Time frame: Up to 24 hours post-injection

  4. Correlation with DLL3 Expression

    Correlation between \[⁶⁸Ga\]Ga-DLL3 PET/CT uptake (SUVmax, SUVmean) and DLL3 expression level by immunohistochemistry (IHC) in biopsied tumor specimens (where available).

    Time frame: At study completion (expected at Month 6)

  5. Target-to-Background Ratio (TBR)

    Quantitative comparison of TBR between \[⁶⁸Ga\]Ga-DLL3 PET/CT and standard scans (FDG or PSMA PET/CT) in identified lesions, with background regions pre-defined as liver, blood pool, and muscle.

    Time frame: Baseline (within 14 days of enrollment)

Other outcomes

  1. Baseline SUVmax of [⁶⁸Ga]Ga-DLL3 PET/CT as a Predictor of Clinical Benefit

    The maximum standardized uptake value (SUVmax) derived from baseline \[⁶⁸Ga\]Ga-DLL3 nanobody PET/CT imaging, measured within 14 days prior to enrollment. The optimal cut-off value for SUVmax will be determined using receiver operating characteristic (ROC) curve analysis to stratify patients into high- vs. low-expression groups. This individual parameter will be evaluated for its ability to predict objective response or progression-free survival benefit from DLL3-targeted therapies (e.g., Tarlatamab).

    Time frame: Baseline (within 14 days of enrollment)

  2. Hazard Ratio (HR) for 24-Month Overall Survival Based on Baseline SUVmax Cut-off

    The hazard ratio (HR) with 95% confidence interval, derived from univariate Cox proportional hazards regression, comparing 24-month overall survival between neuroendocrine neoplasm patients stratified by the optimal baseline \[⁶⁸Ga\]Ga-DLL3 nanobody PET/CT SUVmax cut-off value (high-expression vs. low-expression groups). Overall survival is measured as time (in months) from enrollment to death from any cause.

    Time frame: Baseline (within 14 days of enrollment) and Month 24

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Henke RM, Meredith DM, Borromeo MD, Savage TK, Johnson JE. Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube. Dev Biol. 2009 Apr 15;328(2):529-40. doi: 10.1016/j.ydbio.2009.01.007. Epub 2009 Jan 14. PubMed 19389376 ↗
  • Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. Lancet Oncol. 2024 Aug;25(8):1015-1024. doi: 10.1016/S1470-2045(24)00249-3. Epub 2024 Jun 28. PubMed 38950555 ↗
  • Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y. PubMed 36810079 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality, as this study involves imaging data (PET/CT) that could potentially be re-identifiable. Only aggregate results will be published in peer-reviewed journals.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 85 non-industry phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 83. This study's planned 17 months is below that.

Counting every sponsor, half of 98 studies reached it within 65 months; a quarter within 42 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 29, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
1 site added. Peking University First Hospital is now Recruiting
Show site
  • Department of Nuclear Medicine, Peking University First Hospital · Beijing, China
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Peking University First Hospital · Beijing, ChinaContact added b•••@163.com · •••5252
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Recruiting
    1 site added. Peking University First Hospital is now Recruiting
    Show site
    • Department of Nuclear Medicine, Peking University First Hospital · Beijing, China
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Peking University First Hospital · Beijing, ChinaContact added b•••@163.com · •••5252
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07733024
Lead sponsor
Tingting Yuan
Responsible party
Tingting Yuan (Postdoctoral Fellow; Attending Physician, Peking University First Hospital) — Sponsor-investigator
First posted
Jul 29, 2026
Start date
Jul 6, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Tingting Yuan, MD
Contact
biluohtt@163.com
+86 13051707479

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion